Dymista azelastine/fluticasone: Phase III data

The open-label Phase III MP4000 safety trial in 612 patients with chronic allergic or non-allergic rhinitis showed that continuous treatment with Dymista for 1 year was well tolerated. Additionally, a similar proportion of patients receiving Dymista discontinued the trial due to an adverse event compared to fluticasone alone (2.7% vs. 2.9%). The most common Dymista-related adverse event was dysguesia and there were no significant changes from baseline in serum cortisol levels in either treatment arm. Furthermore, Dymista led to significantly greater relief from nasal symptoms as measured by reflective TNSS vs. fluticasone at months 1-7 and at months 9 and 11. Data were presented at the American Academy of Asthma, Allergy and Immunology meeting in Orlando. ...